Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Improved Modifications Of Nitric Oxide Donating Aspirin (NO-ASA): Getting a Grip On TP53 Mutated High-Risk Chronic Lymphocytic Leukemia (CLL)

Sylvia Krallman, Simon Jonas Poll-Wolbeck, Hanna Flamme, Mark Krueger, Albrecht Berkessel, PhD, Michael Hallek, MD, Karl-Anton Kreuzer, Dr. med.

Blood (2013) 122 (21): 4909.

https://doi.org/10.1182/blood.V122.21.4909.4909

Published: 2013

Journal Articles

Dependency of CLL Cell Survival on Direct Physical Interaction with Bone Marrow Stromal Cells In Vitro Is Largely Outweighed by Secretion of Soluble Factors with Time In Culture

Iris Gehrke, Simon Jonas Poll-Wolbeck, Michael Hallek, Karl-Anton Kreuzer

Blood (2010) 116 (21): 1365.

https://doi.org/10.1182/blood.V116.21.1365.1365

Published: 2010

Journal Articles

High Lymphoid Enhancer-Binding Factor-1 (LEF1) Expression Is Associated with ZAP70 Positivity, Requirement of Treatment, and Fibromodulin (FMOD) Expression In Chronic Lymphocytic Leukemia (CLL)

Felix Erdfelder, Simon Jonas Poll-Wolbeck, Iris Gehrke, Michael Hallek, Karl-Anton Kreuzer

Blood (2010) 116 (21): 1715.

https://doi.org/10.1182/blood.V116.21.1715.1715

Published: 2010

Journal Articles

The Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Possess Strong Inhibitory Effect on Tumor Growth In a CLL-Like Xenograft Mouse Model

Julian Paesler, Iris Gehrke, Regina Razavi, Simon Jonas Poll-Wolbeck, Michael Hallek, M.D., Karl-Anton Kreuzer

Blood (2010) 116 (21): 1393.

https://doi.org/10.1182/blood.V116.21.1393.1393

Published: 2010

Journal Articles

Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) - a Putative Diagnostic Marker for Chronic Lymphocytic Leukemia (CLL).

Sabrina Uhrmacher, Magdalena Hertweck, Julian Paesler, M.Pharm., Felix Erdfelder, Alexandra Filipovich, Simon Jonas Poll-Wolbeck, Regina Razavi, M.Pharm., Rajesh Kumar Gandhirajan, M.Sc., Iris Gehrke, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 1587.

https://doi.org/10.1182/blood.V114.22.1587.1587

Published: 2009

Journal Articles

Evidence for a Pathological Ratio of CD44s/CD44v6 in Chronic Lymphoctic Leukemia (CLL) Cells.

Magdalena Hertweck, Felix Erdfelder, Alexandra Filipovich, Sabrina Uhrmacher, Rajesh Kumar Gandhirajan, Iris Gehrke, Julian Paesler, Regina Razavi, Simon Jonas Poll-Wolbeck, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 2628.

https://doi.org/10.1182/blood.V114.22.2628.2628

Published: 2009

Journal Articles

Selective Targeting of Vascular Endothelial Growth Factor (VEGF) Receptor Signaling with Pazopanib and Vatalanib Induces Apoptosis in Chronic Lymphoctic Leukemia (CLL) Cells in Vitro Inhibits Growth of Human CLL Like Tumor Xenografts in Mice.

Julian Paesler, Iris Gehrke, Regina Razavi, Rajesh Kumar Gandhirajan, Alexandra Filipovich, Magdalena Hertweck, Felix Erdfelder, Sabrina Uhrmacher, Simon Jonas Poll-Wolbeck, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 3451.

https://doi.org/10.1182/blood.V114.22.3451.3451

Published: 2009

Journal Articles

The Para -Isomer of Nitric Oxide Donating Acetylsalicylic Acid (p-NO-ASA) Induces Apoptosis in Chronic Lymphocytic Leukemia (CLL) in Vitro and In Vivo without Gross Systemic Toxicities.

Regina Razavi, M.Pharm., Iris Gehrke, Rajesh Kumar Gandhirajan, Simon Jonas Poll-Wolbeck, Julian Paesler, Felix Erdfelder, Magdalena Hertweck, Alexandra Filipovich, Sabrina Uhrmacher, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 3783.

https://doi.org/10.1182/blood.V114.22.3783.3783

Published: 2009

Journal Articles

Vascular Endothelial Growth Factor (VEGF) Acts Via Auto- and Paracrine Mechanisms as a Critical Microenvironmental Factor for the Survival of Chronic Lymphocytic Leukemia (CLL) Cells.

Iris Gehrke, Julian Paesler, Rajesh Kumar Gandhirajan, Regina Razavi, Simon Jonas Poll-Wolbeck, Alexandra Filipovich, Sabrina Uhrmacher, Felix Erdfelder, Magdalena Hertweck, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 4376.

https://doi.org/10.1182/blood.V114.22.4376.4376

Published: 2009

Journal Articles

Potent Antineoplastic Activity of Two Inhibitors of Lymphoid Enhancer Binding Factor-1 (LEF-1) in Chronic Lymphocytic Leukemia (B-CLL).

Rajesh Kumar Gandhirajan, Iris Gehrke, Alexandra Filipovich, Julian Paesler, Regina Razavi, Felix Erdfelder, Magdalena Hertweck, Simon Jonas Poll-Wolbeck, Sabrina Uhrmacher, Axel Schlösser, M.D., Esther Katharin Schmitt, Ph.D., Guenter Plickert, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 885.

https://doi.org/10.1182/blood.V114.22.885.885

Published: 2009

Journal Articles

Expression of the Transcription Factor Lymphoid Enhancer Binding Factor-1 (LEF-1) Is Correlated to Aberrantly Increased Fibromodulin Transcripts in Chronic Lymphocytic Leukemia (CLL).

Felix Erdfelder, Iris Gehrke, Rajesh Kumar Gandhirajan, Magdalena Hertweck, Regina Razavi, Julian Paesler, Alexandra Filipovich, Sabrina Uhrmacher, Simon Jonas Poll-Wolbeck, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 4589.

https://doi.org/10.1182/blood.V114.22.4589.4589

Published: 2009

Journal Articles

Lack of WNT Pathway Co-Receptors as a Possible Reason for Chronic Lymphoctic Leukemia (CLL) Cells Resistance to Dickkopf-1 (DKK1).

Alexandra Filipovich, Rajesh Kumar Gandhirajan, Iris Gehrke, Julian Paesler, Simon Jonas Poll-Wolbeck, Sabrina Uhrmacher, Magdalena Hertweck, Felix Erdfelder, Regina Razavi, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 1598.

https://doi.org/10.1182/blood.V114.22.1598.1598

Published: 2009

NARROW

Improved Modifications Of Nitric Oxide Donating Aspirin (NO-ASA): Getting a Grip On TP53 Mutated High-Risk Chronic Lymphocytic Leukemia (CLL)

Dependency of CLL Cell Survival on Direct Physical Interaction with Bone Marrow Stromal Cells In Vitro Is Largely Outweighed by Secretion of Soluble Factors with Time In Culture

High Lymphoid Enhancer-Binding Factor-1 (LEF1) Expression Is Associated with ZAP70 Positivity, Requirement of Treatment, and Fibromodulin (FMOD) Expression In Chronic Lymphocytic Leukemia (CLL)

The Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Possess Strong Inhibitory Effect on Tumor Growth In a CLL-Like Xenograft Mouse Model

Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) - a Putative Diagnostic Marker for Chronic Lymphocytic Leukemia (CLL).

Evidence for a Pathological Ratio of CD44s/CD44v6 in Chronic Lymphoctic Leukemia (CLL) Cells.

Selective Targeting of Vascular Endothelial Growth Factor (VEGF) Receptor Signaling with Pazopanib and Vatalanib Induces Apoptosis in Chronic Lymphoctic Leukemia (CLL) Cells in Vitro Inhibits Growth of Human CLL Like Tumor Xenografts in Mice.

The Para -Isomer of Nitric Oxide Donating Acetylsalicylic Acid (p-NO-ASA) Induces Apoptosis in Chronic Lymphocytic Leukemia (CLL) in Vitro and In Vivo without Gross Systemic Toxicities.

Vascular Endothelial Growth Factor (VEGF) Acts Via Auto- and Paracrine Mechanisms as a Critical Microenvironmental Factor for the Survival of Chronic Lymphocytic Leukemia (CLL) Cells.

Potent Antineoplastic Activity of Two Inhibitors of Lymphoid Enhancer Binding Factor-1 (LEF-1) in Chronic Lymphocytic Leukemia (B-CLL).

Expression of the Transcription Factor Lymphoid Enhancer Binding Factor-1 (LEF-1) Is Correlated to Aberrantly Increased Fibromodulin Transcripts in Chronic Lymphocytic Leukemia (CLL).

Lack of WNT Pathway Co-Receptors as a Possible Reason for Chronic Lymphoctic Leukemia (CLL) Cells Resistance to Dickkopf-1 (DKK1).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only